XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 29.81

-4.3%

Dec 2 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (16316)	10/3/2003 6:00:38 PM
From: Cacaito	Read Replies (1) of 17367

xoma can get a lucky hit! Well, I post to the club (did not get there cause my email changed), that xoma needs to distribute bpi widely to clinical researchers like the Dallas one so they have a better chance of a lucky hit. Orphan drug designation, first some degree of efficacy should be seen, then the application for ODD, then complete the phase III. Crohn's trials could have been done that way (but xoma got $10M for it, another $8 for meningo from Baxter, it was not so baxtard after all). Meningo was ODD, really odd!!!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next